Royalty Pharma officer proposes $722K stock sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc officer Marshall Urist reported a proposed sale of 13,684 shares of common stock, with an approximate sale date of May 20, 2026, and an aggregate market value of $721,837.21. The proposed sale is tied to a Rule 10b5-1 plan with a reported adoption or instruction date of February 12, 2026.
Urist also reported selling 13,684 shares on May 14, 2026, for gross proceeds of $726,137.82 during the preceding three months.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Equity Performance Award financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.